Pravastatin

HMG-CoA Reductase Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Pravastatin is an ofp drug in the HMG-CoA Reductase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1991. Its mechanism of action is classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors. DrugCentral lists 3 molecular targets, including Hmgcr, HMGCR and Slc22a6. Recorded indications include Arteriosclerotic vascular disease, Cerebrovascular accident, Familial hypercholesterolemia - heterozygous and Familial type 3 hyperlipoproteinemia.

• Approval status: ofp (first approved 1991 by the FDA).
• Drug class: HMG-CoA Reductase Inhibitor.
• Mechanism of action: Hydroxymethylglutaryl-CoA Reductase Inhibitors.
• Molecular targets: Hmgcr, HMGCR and Slc22a6 (3 listed in DrugCentral).
• Indications: Arteriosclerotic vascular disease, Cerebrovascular accident, Familial hypercholesterolemia - heterozygous, Familial type 3 hyperlipoproteinemia and Hypercholesterolemia and others.
• ATC code: C10AA03 (HMG CoA reductase inhibitors).
• Molecular formula: C23H36O7; molecular weight 424.53 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (11)

• Arteriosclerotic vascular disease
• Cerebrovascular accident
• Familial hypercholesterolemia - heterozygous
• Familial type 3 hyperlipoproteinemia
• Hypercholesterolemia
• Hypertriglyceridemia
• Mixed hyperlipidemia
• Myocardial Infarction Prevention
• Prevention of Transient Ischemic Attacks
• Primary Prevention of Coronary Heart Disease
• Slow Progression of Coronary Artery Disease

Contraindications (37)

• Acute erosive gastritis
• Acute nephropathy
• Alcoholism
• Anemia
• Anemia due to enzyme deficiency
• Breastfeeding (mother)
• Constipation
• Dehydration
• Diarrhea
• Disease of liver
• Disorder of muscle
• Factor II deficiency
• Gastrointestinal hemorrhage
• Gastrointestinal ulcer
• Gout
• Hemophilia
• Hemorrhagic cerebral infarction
• Hypercalcemia
• Hyperparathyroidism
• Kidney disease
• Kidney stone
• Liver function tests abnormal
• Low blood pressure
• Nasal polyp
• Osteolysis
• Peptic ulcer
• Pregnancy, function
• Reye's syndrome
• Rhabdomyolysis
• Sarcoidosis
• + 7 more

Mechanism & targets

• Mechanism of action (MoA): Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Established pharmacologic class: HMG-CoA Reductase Inhibitor

Molecular targets (3)

Target	Gene	Action	Activity
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Hmgcr	unknown	IC50 8.38
3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMGCR	inhibitor	IC50 7.52
Solute carrier family 22 member 6	Slc22a6	unknown	Ki 4.28

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1991-10-31	FDA	—	BRISTOL MYERS SQUIBB

ATC classification

ATC code	Therapeutic hierarchy
C10AA03	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › HMG CoA reductase inhibitors
C10BA03	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Combinations of various lipid modifying agents
C10BA11	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Combinations of various lipid modifying agents
C10BA12	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Combinations of various lipid modifying agents
C10BX02	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: APOE
• FDA label: LDLR

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myalgia	877.7
Amaurosis fugax	359.2
Haemorrhagic stroke	355.7
Pemphigus	330.5
Acute kidney injury	327.3
Ocular discomfort	310.1
Hand deformity	299.4
Tinnitus	291.3
Urinary tract disorder	267.0
Glossodynia	263.4
Synovitis	259.8
Fall	233.7

Chemical structure

• Molecular formula: C₂₃H₃₆O₇
• Molecular weight: 424.53 g/mol
• CAS number: 81093-37-0
• InChIKey: TUZYXOIXSAXUGO-PZAWKZKUSA-N
• PubChem CID: 54687

CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pravastatin used for?

DrugCentral lists the following indications for Pravastatin: Arteriosclerotic vascular disease, Cerebrovascular accident, Familial hypercholesterolemia - heterozygous, Familial type 3 hyperlipoproteinemia, Hypercholesterolemia, Hypertriglyceridemia, Mixed hyperlipidemia and Myocardial Infarction Prevention and others.

How does Pravastatin work?

Pravastatin is classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors; its molecular targets in DrugCentral include Hmgcr, HMGCR (inhibitor) and Slc22a6.

When was Pravastatin first approved?

Pravastatin was first approved by the FDA in 1991.

What drug class does Pravastatin belong to?

Pravastatin is in the HMG-CoA Reductase Inhibitor class.

What is the chemical formula of Pravastatin?

Pravastatin has the molecular formula C23H36O7 and a molecular weight of 424.53 g/mol.

Sources

• DrugCentral drug card 2239 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1144 — compound record and bioactivity
• PubChem CID 54687 — chemical identifiers
• DrugBank DB00175 — drug record
• FDA UNII KXO2KT9N0G — substance identity
• DailyMed: FDA labels for Pravastatin — current prescribing information (label search)
• UniProt P04035 (HMGCR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.